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Introduction
Non-traumatic subarachnoid haemorrhage (SAH) is a devastating neurological condition with an immediate mortality rate of about 12% (Huang and van Gelder, 2002) . Survivors experience significant neurological sequelae, such that recovery to their previous level of functioning is uncommon. Most also experience persistent cognitive problems that interfere with return to employment (Al-Khindi et al., 2010) .
Clinical trials in SAH have most commonly used the modified Rankin score (mRS) (Farrell et al., 1991) and the Glasgow Outcome Scale (GOS) (Jennett and Bond, 1975) or its extended version (GOSE) (Jennett et al., 1981; Wilson et al., 1998) . These scales were developed to categorize outcomes following ischaemic stroke and head injury, respectively, and have well-described limitations when applied to SAH Macdonald et al., 2013b) . Although the exact sources of these limitations are not known, there are some clues. It has limited responsiveness in stroke (Dromerick et al., 2003) , and yet it is applied to SAH, where the multiplicity of pathological processes triggered by ictus complicate recovery compared to stroke. Half the patients with a post-SAH mRS of zero exhibit significant cognitive impairment when evaluated neuropsychologically (Kreiter et al., 2002) , one in three are unable to return to work and one in six have a mood disorder (Quinn et al., 2014) . Hence a mRS of zero after SAH cannot be used to define a good outcome, i.e. it lacks sensitivity, since patients with a mRS of zero have a markedly heterogenous outcome. The GOS has shown similar problems (Hutter and Gilsbach, 1993) .
Although SAH is a form of cerebrovascular insult, it cannot be equated with ischaemic stroke since it has unique pathophysiology and anatomical localization. SAH occurs more frequently in people of working age with young families, so potential loss of quality-adjusted life years and economic impact are disproportionately high (Taylor et al., 1996; Rivero-Arias et al., 2010) . There is also a much higher incidence of post-traumatic stress symptoms after SAH (Powell et al., 2002; Visser-Meily et al., 2013) compared to stroke (Sembi et al., 1998) and trauma (Shalev et al., 1998) . Clearly, the SAH patient experience does not necessarily mirror that of patients with ischaemic stroke and head injury survivors.
A study of six outcome measures developed for conditions other than SAH indicated that none adequately captured the morbidity occurring after SAH (Kim et al., 2005) . Besides the mRS and GOS, these included the Barthel Index, the National Institutes of Health Stroke Score, the Short Form-36 and the Mini-Mental Status Examination. The BICRO39 (Powell et al., 2002) , CLCE-24 , EQ5D (Meyer et al., 2010) , Stroke-Specific Quality of Life (Boosman et al., 2010) and Quality of Life after Brain Injury (Wong et al., 2014) have also been applied to SAH after their development for other conditions, because of the absence of a SAH-specific outcome measure. In an attempt to encompass as many features of SAH impact as possible, a recent study used a booklet of questionnaires including the Self-Report Dysexecutive Questionnaire, the Everyday Memory Questionnaire, Stroke Symptom Checklist, Wimbledon Self-Report Scale, and the needs-based Stroke-Specific Quality of Life scale, to derive a summed patient-reported score (Quinn et al., 2014) . Despite these efforts, an SAH-specific outcome scale is still lacking.
The critical need for a better and more specific outcome measure has been articulated by the Subarachnoid Hemorrhage International Trialists (SAHIT), an international network of SAH investigators (Macdonald et al., 2013a) . To address this unmet need, we set out to develop a condition-specific scale for use in patients who experience SAH, hereafter referred to as the subarachnoid haemorrhage outcome tool (SAHOT). The SAHIT recognized that information on cognitive outcome needs to be well represented but the multiplicity of cognitive tools available render it difficult to decide which to use. We therefore decided to interview a cross-section of patients and find out which patient-reported outcomes, including those in the cognitive domain, were important. At the outset, we set the following requirements for the tool and its development: (i) specific to SAH; (ii) primarily an interval (scalar) measure; (iii) able to assess the full spectrum of disability; (iv) scale development process involving classical and modern psychometric approaches; (v) iterative scale modifications and improvement; (vi) minimal training, cost and instrumentation involved; (vii) patient-reported; and (viii) high acceptability.
Materials and methods

Setting
In a tertiary neurovascular centre in southern England, a multidisciplinary working group was established to develop the tool. The team consisted of experienced professionals and researchers from neurosurgery, neurology and neurovascular nursing backgrounds. The project was covered by National Research Ethics Committee approval (NRES 12/SC/0666) and local institutional approval. All data were collected in a link-anonymized fashion.
Scales used
Since mRS (Farrell et al., 1991) and GOSE (Jennett et al., 1981) are the most widely used outcome measures after SAH, they were considered as gold standards for scale validation in the absence of a SAH-specific measure. The modified version (Farrell et al., 1991) of the Rankin Scale (Rankin, 1957) was used, ranging from 0 (no symptoms at all) to 5 (severe disability); a grade of mRS 6 (death) was added to include mortality (Quinn et al., 2009 ). The extended version (GOSE) (Jennett et al., 1981; Wilson et al., 1998) of the GOS (Jennett and Bond, 1975) was used, ranging from 1 (dead) to 8 (upper good recovery). The BICRO-39 (Powell et al., 2002) , CLCE-24 , Fisher (Fisher et al., 1980) and World Federation of Neurosurgical Societies (WFNS) (Teasdale et al., 1988) were used to describe the populations and further examine SAHOT validity.
Item generation and scale development
SAH-relevant symptoms were first identified using information collected in neurovascular clinics. This was supplemented by an English literature search over the past 20 years, using Google Scholar and Web of Science. Search terms included 'subarachnoid haemorrhage', 'symptom', 'need', 'score', 'scale', 'tool' and 'outcome'. A focus group of 30 SAH patients and their next-of-kin met with the team to discuss the items identified, add any other items deemed important and finalize a first draft of the questionnaire. This draft was piloted by two researchers and further refined in response to feedback with respect to instrument design and usability. It consisted of 60 items covering daily life, cognitive, physical, and behavioural/ psychological consequences of SAH. For each item, respondents were asked to grade perceived change compared to their status immediately prior to the SAH using a 5-point Likert scale (0 = no change; 1 = small change; 2 = moderate change; 3 = large change; 4 = complete change). A 'not applicable' option was available. The direction of change (better or worse) was also recorded.
Clinical implementation
The questionnaire was deployed in the clinical neurovascular service, across in-patients and follow-up clinics. The work was divided into two phases: a development phase (n = 113; 69% clinic attenders and 31% unselected consecutive admissions) and a validation phase (n = 75, 100% unselected consecutive admissions). The questionnaire was administered during a face-to-face consultation, by telephone interview or by post, to both patients and their next-of-kin at 1, 3 and 6 months post-SAH. In the validation phase, GOSE and mRS were coadministered with the SAHOT. BICRO39 and CLCE-24 were administered in a subset of patients at 6 months (n = 19). Scales were administered at 1 month AE 1 week, 3 months AE 2 weeks and 6 months AE 1 month. The assessor did not know prior scores during subsequent time points since scores were calculated and/or tabulated at the end of the follow-up. Scales were administered by the author team consisting of three clinical trainees (S.M., E.C., A.Z.), a neurovascular research nurse (L.F.), a vascular neurosurgeon (D.B.) and a neurologist (I.G.). Several of the team had formal mRS and GOSE training and this was cascaded within the team. Trainees were closely supervised by senior members of the team. In most cases, the same person administered all the scales to an individual patient. The order of the tools was not specified.
Rasch analysis
The performance of the SAHOT scale was tested against the principles of Rasch measurement theory (Rasch, 1980; Tesio, 2003; Tennant et al., 2004; Tennant and Conaghan, 2007) . Briefly, Rasch methodology uses total scores obtained from a scale to rank examinees by their relative ability, and scale items by their relative difficulty, on a single linear continuum or 'ruler', separately and independently from each other. Linear estimates of patient ability and item difficulty are expressed in log odds ratios or logits.
For the purposes of the analysis, data across time points and examinees (patients and next-of-kin) were stacked into a single dataset. Questions left unanswered and 'not applicable' replies were treated as missing data. In a few instances the impact of SAH on certain items was reported as positive rather than negative. These positive changes were rescored as 'no change' as they implied that no change for the worse occurred. Data were analysed using the Rasch-based software RUMM2030 (Andrich, 2012) .
Volumetric assessment of bleed size
In the development phase, volumetric blood clot volume was used for the sole purpose of testing the SAHOT's convergent validity. CT imaging of the head was available for 60 patients; there was no significant difference in the demographics and baseline characteristics of these 60 patients compared to the whole development cohort. Volumetric blood clot volume was quantified using MIPAV (Medical Image Processing, Imaging and Visualization) v7.2. CT images were only included in the analysis if acquired using the same imaging protocol within the first 3 days post-SAH, using contiguous slices. Image radiodensity threshold was set between 50 and 80 Hounsfield units, and converted to a binary mask. Regions of interest representing subarachnoid and total blood clot were drawn manually on each slice, and grouped into single 3D volumes. To check reliability, the image processing operator was presented with a test set of CT scans consisting of five control cases and five SAH cases that had been previously quantified, in a blinded fashion. In the control cases, blood volume was zero, while in the SAH cases, the intra-operator coefficient of variation was 10.2%.
Statistics
Excel v15 and SPSS v22 were used. Data distribution was explored graphically and using the Kolmogorov-Smirnov test, and parametric or non-parametric statistical tests were used accordingly. Since there was no evidence of differential item functioning by respondent, construct validity and discrimination were studied using patient scores and, when not available, next-of-kin scores to maximize sample size. Since there was evidence of differential item functioning by time point, construct validity was studied at the middle time point, except for BICRO39 and CLCE-24, which were only administered at 6 months. Rasch-derived person location estimates were used during exploration of validity, discrimination, responsiveness and sample size calculations. Linear, logistic and ordinal regressions were performed with the following independent variables: age, gender, Fisher grade, WFNS, presence or absence of aneurysm, clipping versus coiling, and time from SAH, first in univariate then in multivariate mode. For simulation, we created three synthetic datasets, each consisting of two groups (placebo and treatment with a 20% difference in proportion of mRS = 0, GOSE = 8 or ordinal SAHOT = 1).
This was done using random sampling with replacement. As an example based on mRS = 0, the treatment group was generated by adjusting the proportion of sampling within the mRS = 0 stratum to achieve the desired difference in the proportion of mRS = 0 compared to the placebo group. The placebo group was generated by sampling without adjustment. For each dataset, the sampling was performed 10 000 times to ensure constancy in representation of scores of the other two scales (in this example, GOSE = 8 and ordinal SAHOT = 1). The same was performed for a second and third simulation based on a 20% difference in proportion of GOSE = 8 and ordinal SAHOT = 1.
Results
Cohort characteristics and SAHOT usability
Demographics and SAH characteristics of the populations examined by the SAHOT are summarized in Table 1 . Twenty-eight per cent were non-aneurysmal after extensive investigation culminating with catheter angiography. All patients and next-of-kin who were approached completed the scale, which took $30 min to finish. The final versions of the SAHOT used in both development and validation phases are in Supplementary material.
Development phase: Rasch-based SAHOT development
Rasch analysis was performed in the development phase to guide construction of the questionnaire. Initial analysis indicated that four items did not contribute to measurement of SAH impact, with poor item fit statistics and poor discrimination between groups with different degrees of SAH impact. These items were as follows: 'Work (i.e. number of working hours and how much one can do at work)', 'Income (gross income)', 'Driving', and 'Headaches'. The items were discussed in a subsequent focus group with SAH patients and professionals, where it was felt that the low prevalence of 'Work', 'Income' and 'Driving' amongst participants prior to SAH, and the ubiquitous nature of 'Headaches' were the likely reasons underlying the items' poor performance. The four items were therefore removed prior to further analyses, leaving a scale of 56 items on which the results presented are based. While analysis outcomes for the 60-item scale are not presented, all aspects of scale performance remained unchanged or improved following their removal.
Unidimensionality
The person separation index (Andrich, 1982) was 0.94, above the threshold of 0.9 indicative of unidimensionality. Item fit residuals and chi-square probabilities are presented in Table 2 . For fit residuals we used the threshold value 5 AE2.5 ($99% significance) to determine misfit to model expectations. Chi-Square probabilities are reported with Bonferroni adjustments to 0.0025.
Targeting
There were no ceiling effects from severely disabled patients in this dataset. Seven data points from three patients and four next-of-kin manifested floor scores (indicating no SAH impact), representing 3% of all data points. This left 228 Supplementary Fig. 1 .
Differential item functioning
To study whether patients responded differently from their next-of-kin, and whether items performed differently at the time points examined, differential item functioning by these factors was explored. There was evidence of differential functioning by time point for five of the scale's 56 items based on month of completion: 'Household chores', 'Tolerance of crowded, busy or noisy places', 'Basic self care (e.g. ability to wash, dress)', 'Learning a new skill', and 'Navigational skills (i.e. getting lost)'. There was no evidence of differential functioning by respondent (patient versus next-of-kin).
Response dependency
Of 1540 correlations between item residuals, 34 (2.2%) were greater than the conventionally accepted threshold of AE 0.3, indicating a small degree of non-random item covariance and possible redundancy between some items.
Performance of item scoring categories
Using the original five scoring categories, category thresholds were disordered (Linacre, 1999) in 45/56 items (80.4%). Supplementary Fig. 2A illustrates the pattern of ordered thresholds expected for the five SAHOT categories. Supplementary Fig. 2B illustrates the category probability curves for one of the disordered items. The probability curves for categories 1 and 2 are flat, indicating that the likelihood of an individual being assigned grade 1 or 2 is extremely low. Furthermore, at no point in the continuum are grades 1 or 2 the most likely received for this question. Similar disordering occurs in the same categories for all other items. The problem of disordered categories was addressed by collapsing the second and third categories ('small change'; 'moderate change'), and the fourth and fifth categories ('large change'; 'complete change'), producing a three-category scoring system for analysis purposes. Collapsing categories significantly reduces disordered thresholds at the potential expense of reducing both the scale's discriminatory ability and responsiveness. However, although the scoring range decreased to 0-112 and scale-to-sample targeting deteriorated, person separation index (0.944) improved slightly. Other statistical indices of scale performance remained unchanged (Table 2 ).
Development phase: the SAHOT ordinal scale
Because of its interval nature, a Rasch-based scale is unable to include mortality within its spectrum, since the interval between mortality and the data point representing the poorest outcome cannot be measured on the same scale. To be able to include mortality within the same tool, the SAHOT logit metrics were subsequently graded into categories, based on their standard errors, according to the method of Wright (2001) . Eight statistically different separation units were identified; in addition to death this resulted in nine ordinal categories. A nomogram is provided for transformation of raw scores to logits and ordinal categories (Table 3 ).
Development phase: traditional scale analyses of SAHOT Convergent and discriminant validity
Convergent validity of the SAHOT (Cronbach and Meehl, 1955) was studied via its correlation with the mRS and GOSE, and with prognostic variables (baseline clinical status and blood clot volume). The SAHOT correlated highly with the mRS and GOSE (Table 4) . Although not commonly used in SAH, the cognitive scale CLCE-24 has been shown to correlate with GOS after SAH , and it also correlated with the SAHOT in this study. The SAHOT correlated better with CLCE-24 (r = 0.813, P 5 10 À4 ) than either mRS (r = 0.325, P = 0.174) or GOSE (r = À0.622, P 5 10
À2
). The SAHOT also correlated positively with prognostic variables, including the WFNS scale (measure of baseline clinical status), Fisher grade and ), the interval SAHOT was sensitive to WFNS (b = 0.322, P 5 10
À3
) and aneurysmal versus non-aneurysmal aetiology (b = 0.178, P = 0.038), but not to age and Fisher score. A similar pattern was seen with dichotomized mRS (0-2 versus 3-6) and GOSE (1-4 versus 5-8) in multivariate logistic regression. It was not possible to accommodate the three scales (ordinal SAHOT, mRS and GOSE) on the same multivariate ordinal regression model due to violation of the proportional odds assumption.
Discriminant validity of the SAHOT (Cronbach and Meehl, 1955) was explored via its correlations with the BICRO39 (a scale that measures psychosocial functioning) and age, and as expected the scale failed to correlate meaningfully with either factor (Table 4) . BICRO39 is a specific scale and does not correlate with overall outcome after SAH as measured by the GOS (Powell et al., 2004) .
Discrimination between individuals
There was a wide range of scores for each mRS and GOSE category, suggesting that the SAHOT may tell apart individuals with the same mRS or GOSE scores on the basis of measured SAH impact (Fig. 1) . This effect was more pronounced in patients with an apparently good outcome as indicated by low mRS and high GOSE categories (Fig. 1) .
In order to study further the discrimination between patients with an apparently good outcome, a treatment trial resulting in a 20% difference in the proportion of the best outcome (mRS = 0) was simulated ( Table 5) . The difference in proportion of the best outcome between the two arms was 12.2% and 9.1% as measured by the ordinal SAHOT = 1 and GOSE = 8, respectively. In a similar simulation i.e. modelling a 20% difference in the proportion of GOSE = 8, the corresponding difference in ordinal SAHOT = 1 and mRS = 0 was 7.8% and 5.9%, respectively. Finally in a third simulation i.e. with a 20% difference in the proportion of ordinal SAHOT = 1, the difference in proportion between the two groups was 13% and 12.9% for ordinal mRS = 0 and GOSE = 8, respectively.
In keeping with the observed incongruency between the ordinal SAHOT, mRS and GOSE, the frequency histograms of the three scales show a markedly different distribution (Fig. 2) .
Responsiveness
Responsiveness of the SAHOT was assessed by measuring its ability to detect improvement with time, between the 3 and 6 month time points, using Wilcoxon Signed Ranks test and effect size (Kazis et al., 1989) (Table 6 ). Conventionally, effect size values of 0.2-0.49 are defined as small, 0.5-0.79 as moderate and 50.8 as large (Cohen, 1960) . Results were compared with indices obtained for the mRS and GOSE. The SAHOT and GOSE were significantly responsive, and their effect sizes were similar. The mRS was not able to detect pairwise change between the two time points.
Sensitivity analysis: aneurysmal cases
The SAHOT was developed as a tool for spontaneous (i.e. non-traumatic) SAH, irrespective of presence or absence of an aneurysm. Drug treatment studies have so far tended to exclude non-aneurysmal SAH, partly since the effect of aneurysm repair procedures are an important determinant of clinical outcome after SAH. Therefore, a sensitivity Rasch analysis of the SAHOT was performed using data from patients with aneurysmal SAH only. The baseline demographic and clinical characteristics of this sub-population are shown in Supplementary Table 1. The same four SAHOT items described above again exhibited poor item fit statistics and poor discrimination between groups with different degrees of SAH impact, resulting in the same 56-item questionnaire. There were no ceiling effects from disabled patients. Based on the 56-item format, six data points from three participants manifested floor scores (indicating no SAH impact), representing 4% of all data points i.e. similar to Rasch analysis of the whole population. This A treatment trial resulting in a 20% difference in the proportion of the best outcome (first column: mRS = 0, GOSE = 8, or ordinal SAHOT = 1) was simulated. The second to fourth columns show the resulting difference in the proportion of the best outcome (mRS = 0, GOSE = 8, or ordinal SAHOT = 1).
it still indicated suboptimal targeting. Response dependency was similar. Relative person and item location distributions are graphically mapped on the same continuum of SAH impact in Supplementary Fig. 3 . Traditional psychometric evaluation of the SAHOT in aneurysmal-only cases is presented in Supplementary Tables 3 and 4 , and Supplementary Fig. 4 . The validity (Supplementary Table  3 ), discriminatory ability ( Supplementary Fig. 4 ) and responsiveness (Supplementary Table 4 ) was similar to the SAHOT as applied to the whole population. The only differences were that correlation of the SAHOT with blood clot volume (Supplementary Table 3 ) and GOSE responsiveness (Supplementary Table 4 ) lost significance, though a trend persisted in both cases. Since the number of patients is smaller in this sensitivity analysis (versus the whole study population), and it was performed post hoc, caution needs to be exercised when making comparisons of scale performance metrics.
Validation
To validate the optimized version of the SAHOT in a busy clinical setting, it was administered to a separate cohort of unselected SAH patients admitted to our Centre (n = 75), together with the mRS and GOSE. The stems of eight questions were rephrased after feedback received from patients during the work above (three reworded, explanation contracted in three, and explanation expanded in two stems).
In keeping with the above-described Rasch-based optimization findings, a 3-point Likert scale (0 = no change; 1 = some change; 2 = large or severe change) was used, together with a 'not applicable' option. Also, the four items that did not contribute to measurement of SAH impact were excluded, resulting in a 56-item questionnaire (Supplementary material). Ordinal SAHOT scores, derived using the nomogram in Table 3 , correlated highly with the mRS (r = 0.764, P 5 10
À19
) and GOSE (r = 0.793, P 5 10
À21
).
Discussion
The aim of this study was to address limitations of instruments including the mRS and GOSE in measuring SAH impact, by developing a new condition-specific instrument, which measures change in the patient's level of functioning. The SAHOT was founded on a core set of changes in physical, cognitive and social functioning reported by SAH patients and their next-of-kin, refined using Rasch methodology, and validated using both Rasch-based and classical approaches.
Comparison of SAHOT to GOS and mRS
Currently, the GOS and mRS are the most commonly used outcome scales in SAH. The SAHOT represents a substantial improvement on these scales. SAHOT represents the cognitive element better, correlating more closely than the GOSE with the CLCE-24, a cognitive assessment tool (van Heugten et al., 2007) ; the mRS did not correlate with the CLCE-24. All three scales correlated with the WFNS, with correlation coefficients of 0.345 (P = 0.025), 0.381 (P = 0.013) and 0.486 (P = 0.001) for the 6 month SAHOT, mRS and GOSE, respectively. In multivariate regression, all three scales were sensitive to the WFNS and the presence or absence of an aneurysm, which are known prognostic factors; no other prognostic factors were significant for all three scales in this dataset. The SAHOT could discriminate patients within individual mRS or GOSE categories (Fig. 1) . The SAHOT, mRS and GOSE do not measure the same construct since there was substantial overlap in SAHOT scores across mRS and GOSE categories (Fig. 1) . When a 20% difference in proportion in best outcome (mRS = 0, GOSE = 8 or SAHOT = 1) was simulated, the three scales did not agree with each other, in all three scenarios (Table 5) . This is in keeping with the fact that the scales have been developed for different conditions. Only the SAHOT is SAH-specific. The SAHOT has a number of significant advantages over the mRS and GOSE, namely: (i) it is specific to SAH; (ii) the starting point for its development was as close as possible to SAH patients and their carers; (iii) it incorporates assessment of cognitive, emotional and social domains; (iv) scale development involved both classical and modern psychometric approaches; (v) iterative scale modifications incorporating patient and next-of-kin led to improvement of the scale; (vi) the scale is administered with minimal training, cost and instrumentation; (vii) it is patient-reported; (viii) it has high acceptability; (ix) it is an interval scale enabling linear regression statistical analysis in survivors, yet can include mortality in its ordinal form; (x) it is more responsive than the mRS; (xi) it can discriminate patients with notable differences in SAH impact who otherwise fall within the same mRS and GOSE categories; and (xii) it represents the cognitive element better than mRS and GOSE.
Rasch-based validation and limitations
Rasch analyses indicated that the scale acceptably meets criteria for successful measurement incorporated within the Rasch model. Limitations will now be discussed. The range of SAH impact across our cohort was narrower compared to that represented by the scale. One reason could be that up to 28% had non-aneurysmal SAH (Table 1) , a rate that is remarkably similar to the UK national rate at the time of writing (27.94% over the last 3 years; source UK National SAH database). This rate has probably been increasing due to improved detection of small SAH. Although non-aneurysmal SAH patients do not have as good an outcome as previously thought (Al-Khindi et al., 2010) , they still had better Fisher, WFNS, mRS, GOSE and SAHOT scores, and improved more during the first 6 months post-SAH (data not shown). Rasch analysis excluding non-aneurysmal cases was performed and showed some improvement in targeting, but it is difficult to draw conclusions since the number of data points was fewer compared to the primary analysis. Another reason for mistargeting could be under-representation of highly disabled, institutionalized patients due to difficulty with attending follow-up clinics. Although this study may not have fully reflected the entire breadth of SAH impact, it represents the typical inclusion criteria for SAH clinical studies. Despite these limitations, SAHOT achieved good Rasch measurement qualities, and better targeting by inclusion of more severely disabled patients might have a positive impact on the Rasch metrics.
Some correlations between SAHOT item residuals exceeded the conventional threshold of AE0.3 above which pairs of residuals are not considered independent. This may potentially inflate scale reliability estimates. However the number was small (2.2%) and most values only marginally exceeded the threshold, so no items were removed as this would have resulted in loss of information on the measured construct and therefore scale validity.
Some items manifested differential item functioning by time, which potentially weakens the possibility of meaningfully comparing scores within/across people at different time points. Differential item functioning by time does not equate to responsiveness to time; it occurs when the location estimate of a particular item changes as a result of other factors unrelated to the entity being measured, so that item measures differentially from the rest. This finding needs confirmation and its implications understood better before considering changes to scale content. If a minimal clinically important difference (MCID) for the SAHOT is determined in future studies, its magnitude could be compared against the difference in test scores resulting from differential item functioning by time. If the bias effect is much smaller than the MCID, there would be little risk of confounding the two. Conversely, if the bias approached or exceeded the MCID in magnitude, it could be mistaken for meaningful change.
Knowledge of the mRS and GOSE could not have influenced the SAHOT score for two reasons. First, the SAHOT was directly patient-reported with no operator interference in item scoring, while the mRS and GOSE were administered by the researchers. In cases where the operators were present to observe as part of research, or assist with reading or writing, they were instructed not to assist in interpretation of the questions, although they could make notes if patients asked for clarification to assist the scale development. Second, the overall SAHOT score was computed from the patient responses to the tool items at a different time, in a different location, and not by the same person who administered the mRS and GOSE.
The exact linguistic formulation of SAHOT stems was designed and iteratively refined with patients, so that they are brief and do not require additional explanation over and above the text accompanying them in the tool. Rasch analysis then tested the performance of these items. Translation of this questionnaire into other languages would therefore require revalidation using Rasch analysis.
Traditional scale evaluation
The SAHOT was found to have good convergent and divergent validity, and therefore construct validity. Correlations with Fisher grade and blood clot volume were modest, in keeping with the fact that blood clot volume is only part of a complex set of factors affecting outcome after SAH. When compared to the mRS and GOSE, the SAHOT had a desirable sensitivity, being able to discriminate patients with better outcome on the mRS and GOSE. The SAHOT had excellent responsiveness.
Usability
The use of Rasch-derived person location estimates may be considered a disadvantage in clinical practice due to reliance on Rasch expertise. However, there are several ways by which the use of the SAHOT in clinical services or trials may potentially be facilitated. One can integrate Rasch analysis into an automated data processing pipeline that links primary data input to output of person location estimates. Alternatively, nomograms may be used to enable derivation of person location estimates from summed raw scores, as done previously (Mills et al., 2013) , assuming that the population studied is similar to the population sample used to develop the nomogram.
This scale was used in a busy clinical service, and was found to be usable. Its usability when completed by patients or next-of-kin on their own was not formally tested, but we did not encounter issues that suggest this will be problematic. The SAHOT is patient-reported while the mRS and GOSE are scored by the assessor. Even if the SAHOT needs to be administered to the patient by a clinician or carer, there is no training involved. Rasch analysis did not detect significant differential item functioning between patients and next-of-kin. This may prove useful in several situations, for example if the patient is unable to complete the assessment due to physical, emotional or speech problems. This design has led to remarkable acceptability.
An important issue to consider is the reachability of patients. We retrospectively assessed the proportion of patients who could not be reached with this tool at 3 months after SAH, in a 9-month period within the development phase, in a systematic fashion. Only 5 of 71 patients during this period, i.e. 7%, were judged unreachable, because they were in a district general hospital (n = 3), nursing home (n = 1) or rehabilitation unit (n = 1). Ten patients (14%) had died; these patients could be scored on the ordinal SAHOT, but not the Rasch-based interval SAHOT.
Research tool
While the SAHOT is less usable than the mRS and GOSE in highly disabled (e.g. vegetative) SAH survivors, its strength lies in its sensitivity and responsiveness to change in patients who are not highly disabled. This holds promise for future clinical studies, where the SAHOT should be able to detect changes in patient outcome among survivors that have so far evaded the mRS and GOS.
Although Rasch-based scales are superior to ordinal scales, they cannot deal with mortality, which is an important aspect of outcome in clinical trials. One possible solution is to report mortality separately. If mortality rate is lower in the experimental versus control arms, a situation may arise whereby the Rasch-based SAHOT outcome of the experimental arm may be paradoxically reduced as a result of the addition of poorly-performing survivors to that arm. In this situation, sensitivity analysis with an ordinal scale able to incorporate mortality is called for. Analysis of the SAHOT as an ordinal scale showed that it had excellent construct validity and was responsive, so that the same questionnaire can double up as an interval and ordinal scale.
Post-traumatic stress disorder
Post-traumatic stress disorder (PTSD) affects up to a third of patients after SAH (Berry, 1998; Noble et al., 2008; Visser-Meily et al., 2013) . Studies have shown that this is unrelated to the clinical characteristics of SAH (Noble et al., 2008; Visser-Meily et al., 2013) . Instead PTSD is related to the stress occurring post-ictally secondary to maladjustment (Baisch et al., 2011) , and can be explained by coping style (Noble et al., 2008; Visser-Meily et al., 2013) and perhaps prior psychiatric morbidity (Hedlund et al., 2011) . It is possible that PTSD may influence SAH outcome as measured by SAHOT, mRS and GOSE scales. This hypothesis can be tested in future studies by specifically measuring PTSD, with for example the Impact of Event Scale (Witteveen et al., 2005) , to determine the proportion of variance in SAHOT, mRS and GOSE that can be explained by PTSD. If the influence of PTSD is significant and substantial, it should perhaps be considered as a covariate in clinical trials of drugs targeting the biology of SAH, since PTSD would usually not be amenable to modification by such drugs.
Future directions
The SAHOT is the first SAH-specific outcome measure, developed with modern Rasch techniques, with acceptable scale properties. Future research efforts will concentrate on developing the SAHOT into an electronic format for selfreporting, external validation in other centres and across different languages and cultures, demonstrating responsiveness of the scale to effective treatments, and working with regulatory authorities and decision-makers towards its acceptance as a clinical trial outcome.
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